In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)

By Nechansky Andreas   Koller Iris   Kircheis Ralf  

Pharmaceuticals, Vol. 3, Iss. 6, 2010-06 ,pp. : 1887-1891

MDPI

Access to resources Recommend Favorite

Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues

By Nandakumar Kutty Selva  

International Journal of Molecular Sciences, Vol. 19, Iss. 3, 2018-02 ,pp. : 677-677

MDPI

Access to resources Recommend Favorite

IgG and IgA with Potential Microbial-Binding Activity Are Expressed by Normal Human Skin Epidermal Cells

By Jiang Dongyang   Ge Jing   Liao Qinyuan   Ma Junfan   Liu Yang   Huang Jing   Wang Chong   Xu Weiyan   Zheng Jie   Shao Wenwei   Lee Gregory   Qiu Xiaoyan  

International Journal of Molecular Sciences, Vol. 16, Iss. 2, 2015-01 ,pp. : 2574-2590

MDPI

Access to resources Recommend Favorite

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1

By Sochaj-Gregorczyk Alicja M.   Ludzia Patryk   Kozdrowska Emilia   Jakimowicz Piotr   Sokolowska-Wedzina Aleksandra   Otlewski Jacek  

International Journal of Molecular Sciences, Vol. 18, Iss. 8, 2017-08 ,pp. : 1688-1688

MDPI

Access to resources Recommend Favorite

Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders

By Sánchez Gomar Ismael   Díaz Sánchez María   Uclés Sánchez Antonio José   Casado Chocán José Luis   Suárez-Luna Nela   Ramírez-Lorca Reposo   Villadiego Javier   Toledo-Aral Juan José   Echevarría Miriam  

International Journal of Molecular Sciences, Vol. 17, Iss. 8, 2016-07 ,pp. : 1195-1195

MDPI

Access to resources Recommend Favorite